CDSCO notice, dated May 4, 2026, stated that long-pending applications on the SUGAM portal awaiting query response will be rejected. It directs all applicants to respond to regulatory queries within 30 days of issuance. The notice highlights that numerous applications...
Central Drugs Standard Control Organization (CDSCO) is the apex regulatory body for all medical devices in India. The CDSCO MD5 license grants the permission to manufacture class A and B medical devices in India. Class A and B medical devices are low to moderate risk...
Conducting clinical performance evaluation is critical to ensure the IVDs are accurate and reliable. Notably, IVD clinical performance evaluation is regulated in India. You have to mandatorily secure the MD 25 license to conduct clinical performance evaluation for new...
The Indian cosmetics industry is booming. Market experts have predicted a bright future for the Indian cosmetics industry in the next 5 to 10 years. Notably, all cosmetics and beauty products entering the Indian market are heavily regulated for the safety of Indian...
Starting a drug manufacturing business in India in 2026 offers strong potential. Rising domestic demand, global export opportunities, and supportive government policies are the driving factors for this booming industry. However, success requires strict compliance with...